- Investing Ideas
- /
- U.S. Biotech Stocks
U.S. Biotech Stocks
Results
442
Even though biotechnology stocks can be very risky, they can also offer some of the biggest rewards with huge profits on offer when you find the right one. The companies below all have reasonable balance sheets and value, giving the best chance of finding a gem.
442 companies
Madrigal Pharmaceuticals
Market Cap: US$9.9b
A biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.
MDGL
US$426.84
7D
2.3%
1Y
97.4%
Revvity
Market Cap: US$9.8b
Provides health sciences solutions, technologies, and services.
RVTY
US$83.04
7D
-5.4%
1Y
-34.3%
Qiagen
Market Cap: US$9.8b
Provides sample to insight solutions that transform biological samples into molecular insights in the Netherlands and internationally.
QGEN
US$43.93
7D
-4.0%
1Y
-5.1%
Verona Pharma
Market Cap: US$9.2b
A biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs.
VRNA
US$106.39
7D
0.09%
1Y
276.5%
Halozyme Therapeutics
Market Cap: US$9.1b
A biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally.
HALO
US$75.64
7D
-0.2%
1Y
35.4%
Caris Life Sciences
Market Cap: US$9.0b
An artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally.
CAI
US$30.44
7D
-9.2%
1Y
n/a
Avantor
Market Cap: US$8.3b
Engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa.
AVTR
US$12.01
7D
-3.1%
1Y
-53.2%
Revolution Medicines
Market Cap: US$8.3b
A clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers.
RVMD
US$43.54
7D
-0.6%
1Y
-2.9%
Bio-Techne
Market Cap: US$8.2b
Develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide.
TECH
US$51.22
7D
-0.6%
1Y
-31.7%
Jazz Pharmaceuticals
Market Cap: US$7.8b
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally.
JAZZ
US$129.59
7D
0.04%
1Y
20.1%
Bio-Rad Laboratories
Market Cap: US$7.6b
Manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America.
BIO
US$276.62
7D
-1.3%
1Y
-12.3%
Charles River Laboratories International
Market Cap: US$7.4b
Charles River Laboratories International, Inc.
CRL
US$149.45
7D
-2.1%
1Y
-22.5%
Repligen
Market Cap: US$7.0b
A life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally.
RGEN
US$124.51
7D
4.3%
1Y
-10.8%
Rhythm Pharmaceuticals
Market Cap: US$6.6b
A commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases.
RYTM
US$96.91
7D
0.8%
1Y
85.5%
Legend Biotech
Market Cap: US$6.1b
Through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe.
LEGN
US$32.82
7D
-6.7%
1Y
-29.9%
Axsome Therapeutics
Market Cap: US$5.9b
A biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States.
AXSM
US$118.77
7D
1.8%
1Y
32.1%
Nuvalent
Market Cap: US$5.8b
A clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer.
NUVL
US$79.54
7D
1.1%
1Y
-20.8%
CRISPR Therapeutics
Market Cap: US$5.5b
A gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform.
CRSP
US$61.05
7D
3.4%
1Y
32.9%
TG Therapeutics
Market Cap: US$5.2b
A commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally.
TGTX
US$35.41
7D
10.5%
1Y
51.6%
Merus
Market Cap: US$5.2b
A clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands.
MRUS
US$68.25
7D
0.1%
1Y
43.7%
Bruker
Market Cap: US$5.1b
Develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally.
BRKR
US$32.01
7D
-0.3%
1Y
-52.4%
Krystal Biotech
Market Cap: US$4.8b
A commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States.
KRYS
US$162.00
7D
5.2%
1Y
-9.8%
PTC Therapeutics
Market Cap: US$4.7b
A biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally.
PTCT
US$57.84
7D
-8.0%
1Y
53.6%
Alkermes
Market Cap: US$4.6b
A biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally.
ALKS
US$27.81
7D
-0.2%
1Y
5.2%
Sotera Health
Market Cap: US$4.5b
Provides sterilization, lab testing, and advisory services for the healthcare industry in the United States, Canada, Europe, and internationally.
SHC
US$15.54
7D
-2.7%
1Y
-6.3%
Arcellx
Market Cap: US$4.4b
Together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States.
ACLX
US$78.75
7D
3.0%
1Y
-6.9%
Vaxcyte
Market Cap: US$4.3b
A clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases.
PCVX
US$32.82
7D
6.3%
1Y
-71.1%
Protagonist Therapeutics
Market Cap: US$4.1b
A biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases.
PTGX
US$65.95
7D
6.1%
1Y
46.8%
ADMA Biologics
Market Cap: US$3.8b
A biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.
ADMA
US$15.66
7D
0.6%
1Y
-19.7%
Mirum Pharmaceuticals
Market Cap: US$3.7b
A biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases.
MIRM
US$74.26
7D
1.5%
1Y
90.5%
ACADIA Pharmaceuticals
Market Cap: US$3.6b
A biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States.
ACAD
US$21.21
7D
-14.3%
1Y
37.0%
Zai Lab
Market Cap: US$3.6b
A biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases.
ZLAB
US$32.49
7D
-0.3%
1Y
59.7%
Crinetics Pharmaceuticals
Market Cap: US$3.4b
A clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
CRNX
US$35.18
7D
2.9%
1Y
-30.3%
Ligand Pharmaceuticals
Market Cap: US$3.3b
A biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide.
LGND
US$168.96
7D
2.1%
1Y
71.0%
Scholar Rock Holding
Market Cap: US$3.2b
A biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role.
SRRK
US$33.72
7D
3.8%
1Y
289.8%
Centessa Pharmaceuticals
Market Cap: US$3.2b
A clinical-stage pharmaceutical company, discovers, develops, and delivers medicines.
CNTA
US$23.01
7D
0.2%
1Y
46.8%